CIK 0001720893 · Non-accelerated filer<br>Smaller reporting company
BioXcel Therapeutics, Inc.
Sign in to watch- Ticker
- BTAIQ
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821386754
- Phone
- 203-643-8060
- Business address
- 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 33 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-14 | Mehta Vimal CEO and President | Option exercise · Restricted Stock Units 10b5-1 | −2,609 | 15,657 | ||
| 2024-09-14 | Steinhart Richard I Chief Financial Officer | Option exercise 10b5-1 | +521 | 5,997 | ||
| 2024-09-14 | Steinhart Richard I Chief Financial Officer | Option exercise · Restricted Stock Units 10b5-1 | −521 | 3,127 | ||
| 2024-09-14 | Rodriguez Javier See Remarks | Option exercise 10b5-1 | +521 | 8,915 | ||
| 2024-09-14 | Rodriguez Javier See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −521 | 3,127 | ||
| 2024-09-14 | O'Neill Vincent See Remarks | Option exercise 10b5-1 | +521 | 4,045 | ||
| 2024-09-14 | O'Neill Vincent See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −521 | 3,127 | ||
| 2024-07-22 | O'Neill Vincent See Remarks | Grant or award · Stock Option (right to buy) | +1,875 | 1,875 | ||
| 2024-07-22 | Mehta Vimal CEO and President | Grant or award · Stock Option (right to buy) | +6,250 | 6,250 | ||
| 2024-07-22 | Steinhart Richard I Chief Financial Officer | Grant or award · Restricted Stock Units | +625 | 625 | ||
| 2024-07-22 | Steinhart Richard I Chief Financial Officer | Grant or award · Stock Option (right to buy) | +1,875 | 1,875 | ||
| 2024-07-22 | Wiley Matthew T. See Remarks | Grant or award · Stock Option (right to buy) | +1,875 | 1,875 | ||
| 2024-07-22 | Rodriguez Javier See Remarks | Grant or award · Restricted Stock Units | +625 | 625 | ||
| 2024-07-22 | Rodriguez Javier See Remarks | Grant or award · Stock Option (right to buy) | +1,875 | 1,875 | ||
| 2024-07-22 | Yocca Frank Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +1,875 | 1,875 | ||
| 2024-06-17 | Yocca Frank Chief Scientific Officer | Sale 10b5-1 | −372 | $1.28 | $476 | 13,474 |
| 2024-06-17 | Wiley Matthew T. Chief Commercial Officer | Sale 10b5-1 | −244 | $1.26 | $308 | 3,498 |
| 2024-06-17 | Steinhart Richard I Chief Financial Officer | Sale 10b5-1 | −372 | $1.26 | $470 | 5,476 |
| 2024-06-17 | Rodriguez Javier See Remarks | Sale 10b5-1 | −361 | $1.26 | $456 | 8,394 |
| 2024-06-17 | O'Neill Vincent See Remarks | Sale 10b5-1 | −155 | $1.29 | $199 | 3,524 |
Page 12 of 27 · 521 trades